We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
Our comprehensive sequencing solutions—spanning whole genome sequencing (WGS), whole exome sequencing (WES), and targeted panel sequencing—are crafted to enhance mutation landscape analyses, target discoveries, and tumour mechanism studies.
At CD Genomics, we deliver high-quality solid tumor sequencing solutions tailored for research applications. Our services support a wide range of sample types, enabling accurate detection of tumor-related genomic alterations.
CD Genomics offers multiple solid tumor sequencing solutions to support a wide range of research goals. The comparison guide below helps you select the most suitable strategy based on your sample type, detection sensitivity, and analysis needs.
Feature | Whole Genome Sequencing (WGS) | Whole Exome Sequencing (WES) | 523-Gene Targeted Panel |
---|---|---|---|
Coverage | Base-level across the entire genome | ±50 bp flanking exons | Deep, focused coverage on specific gene regions |
Sequencing Depth | 30× (tumor) / 60× (normal) | 200× (tumor) / 100× (normal) | Avg. 500× (≥1000× in hotspots) |
Variant Types | SNV, Indel, CNV, SV, MSI | SNV, Indel, CNV | SNV, Indel, CNV, gene fusions, TMB, MSI |
Sample Input | ≥50 mg fresh frozen tissue | FFPE (DV200 ≥ 30%) | Biopsy or low-input DNA (≥10 ng) |
Preferred Sample Type | Fresh-frozen tissue | FFPE (stored ≤8 years) | Biopsy, FNA, cfDNA |
Detection Sensitivity | 5% VAF | 1% VAF | 0.5% VAF |
Key Scientific Benefits | Non-coding regulatory region analysis; 3D genome mapping | Cost-effective somatic/germline variant co-analysis | Ultra-sensitive mutation tracking; rapid turnaround |
Ideal Applications | Systematic discovery of novel targets; rare SV research | Pan-cancer mutation profiling; functional validation | Drug resistance mapping; immune microenvironment tracking |
Suggested Models | High-heterogeneity tumors, chromosomal instability models, organoids | Pan-cancer cell lines | Drug selection models, PDX |
Multi-Omics Integration | + Whole-genome methylation | + RNA-Seq, epigenetic regulation | + Longitudinal liquid biopsy, immune repertoire profiling |
At CD Genomics, we’ve built a fully standardized workflow for solid tumor sequencing—guiding your project from experimental design to data publication. Every step is supported by expert consultation to ensure high efficiency and uncompromising data reliability.
Our comprehensive deliverables are designed to power your research from discovery to high-impact publication.
Deliverable | Format | Scientific Value |
---|---|---|
Raw Sequencing Data | FASTQ / BAM | Traceable primary data, meets journal archive requirements |
Variant Analysis Report | VCF / MAF | Comprehensive somatic mutation landscape: SNVs, Indels, CNVs, SVs |
Visualization Report | PDF with figures/tables | Ready for manuscript drafting, data-rich and publication-friendly |
Category | Guidelines |
---|---|
Sample Type | Extracted genomic DNA or FFPE tissue sections |
Purity | OD260/280: 1.8–2.0; OD260/230 ≥ 2.0 |
Concentration | ≥ 20 ng/μL |
Total Yield | ≥ 2 μg |
Storage Conditions | DNA: Store in TE buffer at 4°C for short-term; FFPE: Low-temperature preferred |
Shipping Guidelines | DNA: Ship on dry ice; FFPE: Seal, moisture-proof, avoid heat |
Degradation Criteria | DNA must be intact, no visible degradation (gel image preferred) |
✅ Tip: If your sample is degraded, low-concentration, or requires DNA extraction, we offer pre-evaluation and rescue protocols tailored to ensure sequencing success.
CD Genomics offers robust sequencing solutions tailored to the unique challenges of cancer research. Whether you're investigating tumour initiation, resistance mechanisms, or new drug targets, our platforms deliver the high-resolution data you need.
Cancer Driver Gene Discovery
Identify high-impact mutations that drive tumour progression and reveal novel therapeutic targets.
Comprehensive Mutation Profiling
Detect and catalogue SNVs, Indels, CNVs, and structural variants for a complete mutation landscape.
Molecular Subtyping & Stratification
Classify tumours based on genomic signatures to guide personalised research or biomarker studies.
Drug Response & Resistance Mechanism Analysis
Uncover the genetic alterations linked to therapy efficacy and resistance development.
Clonal Evolution & Tumour Heterogeneity
Map subclonal architecture and evolutionary dynamics to better understand disease progression.
Neoantigen Prediction & Tumour Immunogenomics
Integrate mutation data to assess TMB and identify potential neoantigens for immunotherapy research.
Selecting the right sequencing partner can directly impact the success of your cancer study. Here's why global researchers trust CD Genomics:
We leverage Illumina NovaSeq and rigorous QC pipelines to deliver accurate, high-depth sequencing—ideal for detecting low-frequency variants and complex tumour genomes.
Choose from whole-genome (WGS), whole-exome (WES), or 500-gene panel sequencing. Our workflows adapt to discovery, mechanistic, or translational research goals.
Receive publication-ready reports with detailed variant annotation, TMB scoring, and pathway analysis—accelerating time to results and boosting manuscript quality.
Our team brings years of solid tumour research experience and offers full support from experimental design to data interpretation.
Please submit a detailed description of your project. We will provide you with a customized project plan to meet your research requests. You can also send emails directly to info@cd-genomics.com for inquiries.
Please fill out the form below: ×